Global Personalized Cancer Medicine Competitive Landscape Professional Research Report 2024

Global Personalized Cancer Medicine Competitive Landscape Professional Research Report 2024

Research Summary

Personalized cancer medicine, also known as precision oncology or personalized oncology, refers to an approach to cancer treatment that takes into account the unique genetic and molecular characteristics of an individual＇s cancer to tailor therapies specifically to that patient. This approach recognizes that cancer is not a single disease but rather a complex group of diseases with diverse underlying genetic mutations and molecular alterations. By analyzing the genetic profile of a patient＇s tumor through techniques such as genomic sequencing, molecular profiling, and biomarker analysis, oncologists can identify specific genetic mutations or biomarkers driving the cancer＇s growth and progression. Based on this information, personalized treatment plans can be developed to target the underlying molecular abnormalities with precision-targeted therapies such as targeted therapies, immunotherapies, or combination therapies. Personalized cancer medicine aims to maximize treatment efficacy while minimizing side effects by selecting therapies that are most likely to be effective for each individual patient based on their unique tumor biology. This approach has revolutionized cancer care by allowing for more precise and effective treatments, leading to improved outcomes and quality of life for many cancer patients.

According to DIResearch's in-depth investigation and research, the global Personalized Cancer Medicine market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.

The major global manufacturers of Personalized Cancer Medicine include AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, GSK, Exelixis, Regeneron, Innovent, Hengrui Medicine etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.

This report studies the market size, price trends and future development prospects of Personalized Cancer Medicine. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Personalized Cancer Medicine market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Personalized Cancer Medicine market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Personalized Cancer Medicine industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Personalized Cancer Medicine Include:

AbbVie

Johnson & Johnson

Novartis

Gilead Sciences

Roche

Bristol-Myers Squibb

Amgen

AstraZeneca

Merck & Co

Takeda

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer

GSK

Exelixis

Regeneron

Innovent

Hengrui Medicine

Personalized Cancer Medicine Product Segment Include:

Cancer Immunotherapy

Targeted Therapy

Personalized Cancer Medicine Product Application Include:

Lung Cancer

Breast Cancer

Prostate Cancer

Blood-related Cancer

Other

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Personalized Cancer Medicine Industry PESTEL Analysis

Chapter 3: Global Personalized Cancer Medicine Industry Porter’s Five Forces Analysis

Chapter 4: Global Personalized Cancer Medicine Major Regional Market Size and Forecast Analysis

Chapter 5: Global Personalized Cancer Medicine Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Personalized Cancer Medicine Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Personalized Cancer Medicine Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Personalized Cancer Medicine Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Personalized Cancer Medicine Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Personalized Cancer Medicine Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Personalized Cancer Medicine Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Personalized Cancer Medicine Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources